Investing has become more and more cautious lately. I don’t dare touch shady platforms, and I steer clear of projects without any background. With the little spare money I’ve saved up, finding a trustworthy place to put it feels harder than climbing to the sky.

But a turning point came pretty suddenly—a while ago I saw some news that a publicly listed financial company on the NYSE, Pineapple Financial, directly invested $100 million into Injective to build a digital asset reserve, and kept buying INJ on the secondary market. That move got me interested; following institutions is definitely better than fumbling around on my own, right? Now, every night before bed, I check my holdings. To be honest, I sleep a lot more soundly.

Why do I dare to follow? It comes down to trust and credibility. Everyone knows how strict compliance reviews are for companies listed on the NYSE—you can’t just bluff your way through with a random PPT. If they’re willing to put real money into Injective, the logic is simple—they believe in the project’s technical direction. After all, Injective is the first in the industry to put real-world assets like traditional government bonds and Nvidia stock on-chain. RWA is a huge trend on its own.

What’s even more important is that $100 million is no small sum, and institutions make decisions with far more careful analysis than we do when buying groceries. Now that a public company is directly coming in and building a position, it’s like giving Injective two stamps of approval—proven technology and capital recognition. This kind of setup is way more reliable than just reading a white paper or listening to community hype.